LumiThera Inc.: LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, multi-center clinical trial

Related Keywords

Sonoma ,California ,United States ,San Diego ,America ,Dennis Riedl ,Clark Tedford ,Allison Dabney ,Quan Dong Nguyen ,Glenn Jaffe ,Diopsys Inc ,Lumithera Inc ,Retina Division ,Lumithera Diagnostics Inc ,Excellence Program ,Stanford University On ,Duke Reading Center ,Food Drug Administration ,Duke University ,Byers Eye Institute ,Byers Eye Institute At Stanford University ,Age Related Macular Degeneration ,Chief Medical Officer ,Latin America ,Duke Reading ,Stanford University ,Valeda Light Delivery System ,Eye Meeting ,Delivery System ,Registration Device ,Adaptdx Pro ,Lumithera Diagnostics ,Lumithera ,Nnounces ,Sustained ,Vision ,Improvement ,Months ,Elated ,Macular ,Regeneration ,Subjects ,Rom ,Ightsite ,Linical ,Trial ,Data ,